Dow Jones Newswires 
(4/27, Dooren, Subscription Publication) reports that the Food and
Drug Administration has approved the use of Novartis AG's Afinitor
(everolimus) for the treatment of non-cancerous kidney tumors caused by a
rare genetic disease called tuberous sclerosis complex (TSC) not
requiring immediate surgery. Since 2009, the medication has been used
in the US for treating kidney cancer when other medications fail. About
40,000 US patients reportedly suffer from the
disease.
(4/27, Dooren, Subscription Publication) reports that the Food and
Drug Administration has approved the use of Novartis AG's Afinitor
(everolimus) for the treatment of non-cancerous kidney tumors caused by a
rare genetic disease called tuberous sclerosis complex (TSC) not
requiring immediate surgery. Since 2009, the medication has been used
in the US for treating kidney cancer when other medications fail. About
40,000 US patients reportedly suffer from the
disease.
Reuters (4/27) reports that everolimus is the first medication FDA has approved for treatment of these tumors.
(4/27) reports that everolimus is the first medication FDA has approved for treatment of these tumors.
No comments:
Post a Comment